NVCR News and Press, NovoCure Limited From 07/01/21

Borqs Technologies (BRQS) -17%.Verb Technology (VERB) -15%.CureVac (CVAC) -13% on final data from phase 2b/3 trial on COVID vaccine.1stdibs.Com (DIBS) -12%.Newegg Commerce (NEGG) -11%.Weidai (WEI) -11%.NovoCure (NVCR) -10% after final results from mid-stage TTFields liver ...

Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments In patients who completed at least 12 weeks of Tumor Treating Fields treatment, disease control rate was 91% with 18% objective respon...

In 2020 alone, almost 10 million people lost their battle against cancer. However, oncology company NovoCure (NASDAQ: NVCR) and its new category of cancer treatment is improving the lives of patients. And with 1,100% gains since its IPO, it's also improving investors' lives....

Novocure (NVCR) announces that it has advanced a new, flexible torso array into a clinical usability study.The updated array will be tested by patients and their caregivers at four clinical sites in Europe.The new design is intended to improve skin adhesion, to increase degrees-of-motion...

New array intended to increase ease-of-use for torso and abdominal applications Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clin...

As it harnesses the power of an electromagnetic field, NovoCure offers hope to countless patients suffering from aggressive cancers. Tumor Treating Fields are now approved for deadly cancers, including glioblastoma multiforme and mesothelioma. The sales also are heading toward the blo...

Dogecoin (CRYPTO: DOGE) has been all over the news in 2021, and for good reason. By early May 2021, this meme-inspired cryptocurrency had gained over 12,000% since the start of 2021. And even now, when Dogecoin is more than 40% below its all-time high of $0.74, it is still 6,880% up...

Growth stocks are usually known to capitalize off short-term consumer trends. However, the best growth companies are the ones that set aside a portion of their revenues each quarter and reinvest back into innovation. That kind of discipline is extremely hard to come by. Luckily, ...

Novocure (NVCR) has entered into a clinical trial collaboration agreement with GT Medical Technologies to develop Tumor Treating Fields ((TTFields)) together with GT Medical's GammaTile Surgically Targeted Radiation Therapy ((STaRT)) for treatment of recurrent glioblastoma ((GBM)), an aggress...

SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Z...